YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system.
Location: China, Minhang District
Employees: 51-200
Mentions in press and media 13
| Date | Title | Description |
| 29.08.2024 | YolTech and Salubris: A New Era in Gene Editing for Cardiovascular Health | In the bustling world of biotechnology, partnerships can be the lifeblood of innovation. Recently, YolTech Therapeutics and Salubris Pharmaceuticals forged a significant alliance, aiming to revolutionize cardiovascular treatment in Mainland... |
| 27.08.2024 | YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China | SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris P... |
| 27.08.2024 | YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China | SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris P... |
| 22.08.2024 | YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1 | SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: the first patient has been dosed with YOLT-203, the co... |
| 11.07.2024 | First Patient Dosed in Phase I Clinical Trial of YOLT-201 | SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical... |
| 02.04.2024 | First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH | SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Fa... |
| 27.03.2024 | YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean | SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event... |
| 13.03.2024 | YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024 | SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, ... |
| 04.03.2024 | Landmark Clinical Approval for YOLT-201 Obtained by the NMPA | SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products ... |
| 02.01.2024 | YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024 | SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, recently announced that it will present an overview of its technology and provide corpo... |
Show more